The U.S. Treasury proposed a rule implementing the Comprehensive Outbound Investment National Security Act (COINS), which would severely restrict future U.S. investment in the Chinese biotech sector. The proposal would prohibit U.S. companies from entering financial transactions with Chinese biotech firms and with Chinese manufacturers of biotechnology-related equipment and tools, according to reporting. The proposal is designed to address national-security concerns by adding biotechnology to industries subject to COINS restrictions, alongside sectors such as semiconductors, artificial intelligence and quantum technology. Treasury’s framework reportedly would still allow American drugmakers to buy the rights to medicines invented in China, maintaining a narrower exception than a full investment freeze. For the biotech industry, this shifts dealmaking expectations across venture financing, collaboration structures, and cross-border capital flows—especially where partnerships rely on U.S. participation in the development pipeline. The policy question going forward will be how licensing and joint-development activity is operationalized under the proposed restrictions. The immediate operational relevance is high: U.S. investors and biotech development teams are likely to revisit China-related investment screening, contracting language, and governance structures to align with the proposed regulatory boundary.